P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY

Detalles Bibliográficos
Autores principales: Russo, Domenico, Polverelli, Nicola, Vezzoli, Marika, Santarone, Stella, Castagna, Luca, Onida, Francesco, Bramanti, Stefania, Sorasio, Roberto, Michele Carella, Angelo, Olivieri, Attilio, Vetro, Calogero, Beltrami, Germana, Curti, Antonio, Stefano Luca Bernardi, Massimo, Mancini, Valentina, Musto, Pellegrino, Terruzzi, Elisabetta, Galieni, Piero, Skert, Cristina, Giaccone, Luisa, Cerretti, Raffaella, Borlenghi, Erika, Farina, Mirko, Leoni, Alessandro, Bernardi, Simona, Calza, Stefano, Gheorghiu, Angela, Malagola, Michele, Martino, Massimo, Ciceri, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429467/
http://dx.doi.org/10.1097/01.HS9.0000968916.48200.82
_version_ 1785090720454934528
author Russo, Domenico
Polverelli, Nicola
Vezzoli, Marika
Santarone, Stella
Castagna, Luca
Onida, Francesco
Bramanti, Stefania
Sorasio, Roberto
Michele Carella, Angelo
Olivieri, Attilio
Vetro, Calogero
Beltrami, Germana
Curti, Antonio
Stefano Luca Bernardi, Massimo
Mancini, Valentina
Musto, Pellegrino
Terruzzi, Elisabetta
Galieni, Piero
Skert, Cristina
Giaccone, Luisa
Cerretti, Raffaella
Borlenghi, Erika
Farina, Mirko
Leoni, Alessandro
Bernardi, Simona
Calza, Stefano
Gheorghiu, Angela
Malagola, Michele
Martino, Massimo
Ciceri, Fabio
author_facet Russo, Domenico
Polverelli, Nicola
Vezzoli, Marika
Santarone, Stella
Castagna, Luca
Onida, Francesco
Bramanti, Stefania
Sorasio, Roberto
Michele Carella, Angelo
Olivieri, Attilio
Vetro, Calogero
Beltrami, Germana
Curti, Antonio
Stefano Luca Bernardi, Massimo
Mancini, Valentina
Musto, Pellegrino
Terruzzi, Elisabetta
Galieni, Piero
Skert, Cristina
Giaccone, Luisa
Cerretti, Raffaella
Borlenghi, Erika
Farina, Mirko
Leoni, Alessandro
Bernardi, Simona
Calza, Stefano
Gheorghiu, Angela
Malagola, Michele
Martino, Massimo
Ciceri, Fabio
author_sort Russo, Domenico
collection PubMed
description
format Online
Article
Text
id pubmed-10429467
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104294672023-08-17 P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY Russo, Domenico Polverelli, Nicola Vezzoli, Marika Santarone, Stella Castagna, Luca Onida, Francesco Bramanti, Stefania Sorasio, Roberto Michele Carella, Angelo Olivieri, Attilio Vetro, Calogero Beltrami, Germana Curti, Antonio Stefano Luca Bernardi, Massimo Mancini, Valentina Musto, Pellegrino Terruzzi, Elisabetta Galieni, Piero Skert, Cristina Giaccone, Luisa Cerretti, Raffaella Borlenghi, Erika Farina, Mirko Leoni, Alessandro Bernardi, Simona Calza, Stefano Gheorghiu, Angela Malagola, Michele Martino, Massimo Ciceri, Fabio Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429467/ http://dx.doi.org/10.1097/01.HS9.0000968916.48200.82 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Russo, Domenico
Polverelli, Nicola
Vezzoli, Marika
Santarone, Stella
Castagna, Luca
Onida, Francesco
Bramanti, Stefania
Sorasio, Roberto
Michele Carella, Angelo
Olivieri, Attilio
Vetro, Calogero
Beltrami, Germana
Curti, Antonio
Stefano Luca Bernardi, Massimo
Mancini, Valentina
Musto, Pellegrino
Terruzzi, Elisabetta
Galieni, Piero
Skert, Cristina
Giaccone, Luisa
Cerretti, Raffaella
Borlenghi, Erika
Farina, Mirko
Leoni, Alessandro
Bernardi, Simona
Calza, Stefano
Gheorghiu, Angela
Malagola, Michele
Martino, Massimo
Ciceri, Fabio
P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
title P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
title_full P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
title_fullStr P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
title_full_unstemmed P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
title_short P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
title_sort p502: phase ii study on venetoclax plus decitabine for elderly (≥60 <75years) patients with newly diagnosed high-intermediate risk aml elegible for allo-sct: midterm update of ven-dec gitmo study
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429467/
http://dx.doi.org/10.1097/01.HS9.0000968916.48200.82
work_keys_str_mv AT russodomenico p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT polverellinicola p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT vezzolimarika p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT santaronestella p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT castagnaluca p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT onidafrancesco p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT bramantistefania p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT sorasioroberto p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT michelecarellaangelo p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT olivieriattilio p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT vetrocalogero p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT beltramigermana p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT curtiantonio p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT stefanolucabernardimassimo p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT mancinivalentina p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT mustopellegrino p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT terruzzielisabetta p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT galienipiero p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT skertcristina p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT giacconeluisa p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT cerrettiraffaella p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT borlenghierika p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT farinamirko p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT leonialessandro p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT bernardisimona p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT calzastefano p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT gheorghiuangela p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT malagolamichele p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT martinomassimo p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy
AT cicerifabio p502phaseiistudyonvenetoclaxplusdecitabineforelderly6075yearspatientswithnewlydiagnosedhighintermediateriskamlelegibleforallosctmidtermupdateofvendecgitmostudy

Ejemplares similares